Canadian Urological Association consensus guideline: Management of testicular germ cell cancer

Robert J Hamilton¹, Christina Canil², Noa Shani Shrem², Kopika Kuhathaas³, Maria Di Jiang⁴, Peter Chung⁵, Scott North⁶, Piotr Czaykowski⁷, Sebastien Hotte⁸, Eric Winquist⁹, Christian Kollmannsberger¹⁰, Armen Aprikian¹¹, Denis Soulières¹², Scott Tyldesley¹³, Alan I So¹⁴, Nicholas Power¹⁵, Ricardo A Rendon¹⁶, Martin O'Malley¹⁷, Lori Wood¹⁸

Affiliations

¹ Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
² Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, ON, Canada.
³ Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
⁴ Department of Medicine, Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
⁵ Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.
⁶ Department of Oncology, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
⁷ Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.
⁸ Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada.
⁹ Division of Medical Oncology, Western University and London Health Sciences Centre, London, ON, Canada.
¹⁰ Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
¹¹ Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
¹² Division of Medical Oncology/Hematology, Le Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
¹³ Department of Radiation Oncology, University of British Columbia, BC Cancer Vancouver, Vancouver, BC, Canada.
¹⁴ Department of Urologic Sciences, University of British Columbia, BC Cancer Vancouver, Vancouver, BC, Canada.
¹⁵ Division of Urology, Department of Surgery, Western University, London, ON, Canada.
¹⁶ Division of Urology, Department of Surgery, Capital Health - Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
¹⁷ Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, Canada.
¹⁸ Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

PMID: 35623007
PMCID: PMC9245964
DOI: 10.5489/cuaj.7945

Canadian Urological Association consensus guideline: Management of testicular germ cell cancer

Robert J Hamilton et al. Can Urol Assoc J. 2022 Jun.

. 2022 Jun;16(6):155-173.

doi: 10.5489/cuaj.7945.

Authors

Affiliations

¹ Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
² Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and the University of Ottawa, Ottawa, ON, Canada.
³ Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
⁴ Department of Medicine, Division of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
⁵ Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.
⁶ Department of Oncology, Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
⁷ Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.
⁸ Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, ON, Canada.
⁹ Division of Medical Oncology, Western University and London Health Sciences Centre, London, ON, Canada.
¹⁰ Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
¹¹ Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
¹² Division of Medical Oncology/Hematology, Le Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
¹³ Department of Radiation Oncology, University of British Columbia, BC Cancer Vancouver, Vancouver, BC, Canada.
¹⁴ Department of Urologic Sciences, University of British Columbia, BC Cancer Vancouver, Vancouver, BC, Canada.
¹⁵ Division of Urology, Department of Surgery, Western University, London, ON, Canada.
¹⁶ Division of Urology, Department of Surgery, Capital Health - Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
¹⁷ Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, Canada.
¹⁸ Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.

PMID: 35623007
PMCID: PMC9245964
DOI: 10.5489/cuaj.7945

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Hamilton has been an advisory board member for Astellas, Bayer, Janssen, TerSera; and has participated in clinical trials supported by Astellas, Bayer, Janssen. Dr. Jiang has been an advisory board member for EMD Serono and Pfizer; and has received payment from Amgen, Bayer, EMD Serono, Ipsen, and Janssen Oncology. Dr. Chung has received honoraria from AbbVie, Boston Scientific, TerSera, and Verity; and has participated in clinical trials supported by CTG, ICON, Medivation, Mount Sinai Health Systems, NRG, and Princess Margaret Cancer Centre. Dr. Hotte has been an advisory board member for AAA/Novartis, Astellas, Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, and Seagen; has received honoraria from Astellas, Bayer, BMS, and Janssen; and has participated in clinical trials supported by AAA/Novartis, Astellas, BMS, CCTG, Eisai, Merck, Pfizer, SeaGen, and SignalChem. Dr. Winquist has been an advisory board member for Amgen, Bayer, Eisai, Merck, and Roche; has received an unrestricted educational grant from Eiasi; and has participated in clinical trials supported by Ayala, Eisai, Merck, and Roche. Dr. Aprikian has been an advisory board member for Abbvie, Astellas, and Bayer; and has received honoraria from Abbvie, Astellas, Bayer, Sanofi, and TerSera. Dr. Soulières has been an advisory board member for Adlai-Nortye, BMS, Eisai, Ipsen, Merck, and Pfizer; and has received research grants to his institution from BMS, Eisai, Ipsen, Merck, and Pfizer. Dr. Tyldesley has received honoraria from Bayer, Janssen, and TerSera (prostate cancer); and has participated in clinical trials supported by Janssen (prostate cancer). Dr. So has been an advisory board member for Abbvie, Astellas, Bayer, Janssen, Merck, and TerSera. Dr. Rendon has been an advisory board member for and received honoraria from Abbvie, Astellas, Bayer, Ferring, Janssen, Sanofi, TerSera, and Tolmar; holds investments in Myovant; and has participated in clinical trials supported by Abbvie, Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Myovant, and Sanofi. Dr. Wood has been an advisory board member for AstraZeneca BMS, Ipsen, Merck, and Pfizer (with no financial compensation); and has participated in clinical trials supported by AstraZeneca, BMS, and Merck (compensation to institution). The remaining authors do not report any competing personal or financial interests related to this work.

Figures

**Figure 1**
Clinical stage IIA/IIB non-seminomatous germ cell tumor treatment algorithm. PCRPLND: post-chemotherapy retroperitoneal lymph node dissection.

See this image and copyright information in PMC

References

1. Committee CCSA, Society CC, Canada S, et al. [Accessed November 16, 2021];Canadian Cancer Statistics. 2021 2021 Available at: https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2021-stat....
1. CC Society. Cancerous tumors of the testicle. [Accessed November 16, 2021]. Available at: https://cancer.ca/en/cancer-information/cancer-types/testicular/what-is-....
1. Gurney JK, Florio AA, Znaor A, et al. International trends in the incidence of testicular cancer: Lessons from 35 years and 41 countries. Eur Urol. 2019;76:615–23. doi: 10.1016/j.eururo.2019.07.002. - DOI - PMC - PubMed
1. Harzstark AL, Altschuler A, Amsden LB, et al. Implementation of a multidisciplinary expert testicular cancer tumor board across a large integrated healthcare delivery system via early case ascertainment. Jco Clin Cancer Informatics. 2021;5:187–93. doi: 10.1200/CCI.20.00114. - DOI - PubMed
1. Albany C, Adra N, Snavely AC, et al. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. Ann Oncol. 2018;29:341–6. doi: 10.1093/annonc/mdx731. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Canadian Urological Association consensus guideline: Management of testicular germ cell cancer

Affiliations

Canadian Urological Association consensus guideline: Management of testicular germ cell cancer

Authors

Affiliations

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources

Medical